Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Oct;205(4):1356-1360.
doi: 10.1111/bjh.19590. Epub 2024 Jun 15.

Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study

Angelica Barone  1 , Annalisa Chiappella  2 , Beatrice Casadei  3 , Stefania Bramanti  4 , Silva Ljevar  5 , Patrizia Chiusolo  6 , Alice Di Rocco  7 , Maria Chiara Tisi  8 , Anna Maria Barbui  9 , Mirko Farina  10 , Lucia Brunello  11 , Maria Chiara Di Chio  2 , Mattia Novo  12 , Maurizio Musso  13 , Jacopo Olivieri  14 , Gentiana Elena Trotta  2   15 , Anna Dodero  2 , Antonella Aiello  16 , Paolo Corradini  1   2
Affiliations
Free article
Observational Study

Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study

Angelica Barone et al. Br J Haematol. 2024 Oct.
Free article

Abstract

Secondary primary malignancies (SPM) have been reported after anti-BCMA or anti-CD19 chimeric antigen receptor (CAR)-T-cell therapies. While the cytotoxic effect of antecedent therapies, including chemotherapy and radiotherapy, has been well established, few data are available on risk related to CAR-T immunotherapies. The study aimed to analyse the incidence of SPM in 651 patients enrolled in the Italian prospective observational CART-SIE study. SPMs were documented in 4.3% (28/651), and the most frequent SPMs were haematological malignancies. In conclusion, the frequency of SPMs in our cohort of heavily pretreated patients receiving CAR-T was relatively low and consistent with previous studies.

Keywords: MDS; T‐cell lymphoma; acute leukaemia; immunotherapy; late effects of therapy; malignant lymphomas.

PubMed Disclaimer

References

REFERENCES

    1. Martelin E, Volin L, Itälä‐Remes M, Niittyvuopio R, Lindström V, Heiskanen J, et al. Incidence and risk factors of secondary cancers after allogeneic stem cell transplantation: analysis of a single centre cohort with a long follow‐up. Bone Marrow Transplant. 2019;54(2):334–337. https://doi.org/10.1038/s41409‐018‐0290‐6
    1. Trab T, Baech J, Jakobsen LH, Husby S, Severinsen MT, Eloranta S, et al. Second primary malignancies in patients with lymphoma in Denmark after high‐dose chemotherapy and autologous haematopoietic stem‐cell transplantation: a population‐based, retrospective cohort study. Lancet Haematol. 2023;10(10):e838–e848.
    1. Administration UFAD. FDA Investigating Serious Risk of T‐cell Malignancy Following BCMA‐ Directed or CD19‐Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. 2023.
    1. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five‐year follow‐up of ZUMA‐1 supports the curative potential of axicabtagene ciloleucel in refractory large B‐cell lymphoma. Blood. 2023;141(19):2307–2315. https://doi.org/10.1182/blood.2022018893
    1. Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, et al. Real‐world evidence of Axicabtagene Ciloleucel for the treatment of large B cell lymphoma in the United States. Transpl Cellular Therapy. 2022;28(9):581.e1–581.e8.

Publication types